-transparent.png){kind=logo}
Aclacinomycin A was nonmutagenic, while most anthracycline drugs such as daunomycin and adriamycin are highly mutagenic in a Salmonella test. But its derivative, N-demethylaclacinomycin A, was mutagenic. Similarly, aclavin, a hydrolysis product of aclacinomycin A, was nonmutagenic, but N-demethylaclavin was mutagenic. N-Methyldaunomycin showed only weak mutagenicity, and N-dimethyldaunomycin was nonmutagenic. Thus, the amino moiety of anthracycline glycosides is concluded to be essential for mutagenesis. Bleomycins were nonmutagenic to most Salmonella tester strains such as TA98, TA100 and TA92 and also to a Escherichia coli strain WP2/uvrA. Bleomycins were weakly mutagenic to Salmonella TA102 and TA94 strains which were extremely sensitive to detect DNA cross linking agents.
K Umezawa, and
M Haresaku, and
M Muramatsu, and
T Matsushima
April 1983,
Mutation research,
K Umezawa, and
M Haresaku, and
M Muramatsu, and
T Matsushima
September 1992,
Pharmacology & toxicology,
K Umezawa, and
M Haresaku, and
M Muramatsu, and
T Matsushima
February 1979,
Science (New York, N.Y.),
K Umezawa, and
M Haresaku, and
M Muramatsu, and
T Matsushima
October 1980,
Mutation research,
K Umezawa, and
M Haresaku, and
M Muramatsu, and
T Matsushima
April 1980,
Mutation research,
K Umezawa, and
M Haresaku, and
M Muramatsu, and
T Matsushima
January 1978,
Cancer letters,
K Umezawa, and
M Haresaku, and
M Muramatsu, and
T Matsushima
May 1983,
European journal of cancer & clinical oncology,
K Umezawa, and
M Haresaku, and
M Muramatsu, and
T Matsushima
January 1983,
Annals of the New York Academy of Sciences,
K Umezawa, and
M Haresaku, and
M Muramatsu, and
T Matsushima
November 2000,
Mutation research,
K Umezawa, and
M Haresaku, and
M Muramatsu, and
T Matsushima
July 1994,
Biological & pharmaceutical bulletin,
